10400nok
4,0 %
Date:2026-09-08Time:16:12:51Latest report:Q2-2026List:Oslo BorsTicker:ONCIN
Market Cap:466 mnokEnterprise Value:359 mnokNet Sales:19,5 mnokEarnings:-171,2 mnokEmployees:0ISIN:NO0013711713

Ratios

10-year key figure history for Oncoinvent turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Oncoinvent with index and moving average MA50 and MA200.

Stockprice:104,00
MA50:80,56
MA200:55,48
Price/MA200:87,5 %
RSI (14):70,9
Price/MA50:29,1 %

Description

Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.

Biotechnology